Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Union Minister Prataprao Jadhav terms hypertension a “silent killer”; experts push for early screening, lifestyle correction and wellness-focused healthcare
The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
Subscribe To Our Newsletter & Stay Updated
